The American Journal of Managed Care1mon
Eculizumab Shows Promise in Thymoma-Associated Myasthenia Gravis
Eculizumab effectively reduced MG-ADL scores and corticosteroid use in thymoma-associated myasthenia gravis patients by week 12. The monoclonal antibody targets complement protein C5, preventing ...
Clinical trial: New drug combination reduces anemia in rare blood disorder
A combination treatment has shown promise for treating a rare blood disease, according to a clinical trial published in the ...
Pharmabiz28d
AstraZeneca’s anti-complement medical therapy, eculizumab receives CDSCO approval
AstraZeneca Pharma India received a Central Drugs Standard Control Organisation (CDSCO) permission to import, sale or distribute ‘Eculizumab’ concentrate solution for infusion 300 mg (10mg/ml).
JD Supra9d
UPC Court of Appeal confirms strict approach to correcting patent errors by interpretation
Alexion Pharmaceuticals v Amgen (UPC_Coa-405/2024) and Alexion Pharmaceuticals v Samsung Bioepis NL BV (UPC_CoA-402/2024); December 20, 2024.
Nature5y
How to make random mutagenesis less random
There is an approved treatment — a therapeutic antibody called eculizumab — but its half-life of only 11.3 days means patients need to endure transfusion every two weeks. In 2018, researchers ...
Nature4y
Methods of Diagnosing and Treating CHAPLE, A Newly Identified Orphan Disease: Collaborative Research and Licensing Opportunity
Recent off-label use of a complement inhibiting drug, eculizumab (CD55 inhibitor) was shown to provide a dramatic benefit in patients with CHAPLE disease with an immediate correction of ...